LINE in the 13F filings
Lineage Cell Theraputics In · CUSIP 53566V106
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 18 May 2026
- latest of these filings; the earliest 8 May 2026
- Managers listing it
- 22
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 4 listed it in both
- Shares listed
- 15,639,012
- combined, among listed positions
- Reported value
- $510m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 13 buyers (opened or added shares) and 12 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -2,364,836.
Managers listing LINE in Q1 2026
22 of 22 holders
Largest increases and reductions, by shares
Increases
- AQR Capital Management LLCexisting position · 2,692,234 shares now+1,361,795
- Citadel Advisors LLCexisting position · 480,155 shares now+449,503
- Holocene Advisors LPexisting position · 107,249 shares now+40,387
- Man Group PLCnew position · 35,592 shares now+35,592
- Artisan Partners LPexisting position · 329,491 shares now+34,571
Reductions
- Millennium Management LLCexisting position · 364,068 shares now-276,519
- Baillie Gifford & Coexisting position · 2,555,123 shares now-231,160
- Two Sigma Investments LPexisting position · 99,939 shares now-116,557
- AllianceBernstein LPexisting position · 41,132 shares now-110,257
- Renaissance Technologies LLCexisting position · 292,700 shares now-82,100
New positions and exits
New (5)
Exited (4)
- Capital Research Global Investorswas $98m
- Moore Capital Management LPwas $14m
- Jane Street Group LLCwas $9.6m
- ExodusPoint Capital Management LPwas $390k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2024 | 16 | $1.5bn | 16 | 0 |
| Q4 2024 | 12 | $1.1bn | 9 | 7 |
| Q1 2025 | 9 | $1.3bn | 6 | 3 |
| Q2 2025 | 11 | $1.0bn | 8 | 3 |
| Q3 2025 | 7 | $646m | 4 | 4 |
| Q4 2025 | 6 | $481m | 13 | 12 |
| Q1 2026 | 4 | $341m | 13 | 12 |
| Q2 2026 | 4 | $513m | 9 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
LINE and WELL →LINE and EQIX →LINE and PLD →Choose a stock to compare with LINE →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own LINE, latest filings →Back to the 13F Explorer →